Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Waverley Pharma Inc V.WAVE

Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of human therapeutics focused on oncology. The Company is focused on the generic oncology injectable market in Europe, the United Kingdom (UK), and North America. The Company, through its subsidiaries, has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited, which has granted the Company an exclusive territorial license to market and sell capecitabine in the UK and Germany as well as a non-exclusive territorial license to market and sell temozolomide and erlotinib in the UK. Its generic oncology products include bortezomib and pemetrexed. Bortezomib is an injectable generic chemotherapy drug, developed for the treatment of multiple myeloma and mantle cell lymphoma. Pemetrexed is an injectable generic chemotherapy drug, developed for the treatment of non-small cell lung cancer and pleural mesothelioma.


TSXV:WAVE - Post by User

Comment by AGResearchon Aug 13, 2020 5:27pm
139 Views
Post# 31405659

RE:Bullish Momentum Shift

RE:Bullish Momentum ShiftTake a look at something like THRM for comparison — another company working on saliva based COVID-19 test. It has triple the mkt cap, more than triple the float, tons of cheap paper as low as .05, almost zero in revenues. Current WAVE valuation makes no sense given $1M cash position, 300K+ quarterly revs and no paper overhang. The only issue to date has been market awareness but volume suggests that is changing. Volume also tends to come in before sp move and I don’t think yesterday’s spike was a fluke. Higher low on the chart today. I am very curious to see how it trades towards EOD Friday and whether we see a short squeeze.
<< Previous
Bullboard Posts
Next >>